Cite
HARVARD Citation
Paturel, C. et al. (n.d.). 190P Combination of IPH5201, a blocking antibody targeting the CD39 immunosuppressive pathway, with durvalumab and chemotherapies: Preclinical rationale. Immuno-oncology technology. p. . [Online].